Detalhe da pesquisa
1.
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Blood
; 143(14): 1399-1413, 2024 Apr 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38194688
2.
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Cancer
; 130(2): 287-299, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37801052
3.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38153814
4.
How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
Br J Haematol
; 204(2): 434-448, 2024 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38148564
5.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38012435
6.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol
; 2024 Mar 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38438627
7.
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation.
Eur J Haematol
; 112(6): 938-943, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38332702
8.
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Am J Hematol
; 99(2): 254-262, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38108611
9.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36932983
10.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37354090
11.
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
Br J Haematol
; 202(6): 1087-1088, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37537862
12.
Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
Hematol Oncol
; 41(1): 50-60, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36251440
13.
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
Ann Hematol
; 102(6): 1375-1382, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37079069
14.
Systemic mastocytosis: 2023 update on diagnosis and management in adults.
Expert Opin Emerg Drugs
; 28(3): 153-165, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37256917
15.
Management of polycythemia vera: A survey of treatment patterns in Italy.
Eur J Haematol
; 110(2): 161-167, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36319575
16.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35363892
17.
Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
Br J Haematol
; 198(6): 965-973, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35904979
18.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35137397
19.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34636033
20.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31826340